Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 8/2017

01-10-2017 | Original Article

I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal

Authors: Chae Moon Hong, Choon-Young Kim, Seung Hyun Son, Ji-hoon Jung, Chang-Hee Lee, Ju Hye Jeong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn

Published in: Annals of Nuclear Medicine | Issue 8/2017

Login to get access

Abstract

Objective

The aim of this study was to assess I-131 biokinetics in thyroid cancer and remnant tissue in patients with differentiated thyroid cancer using whole-body scan (WBS) and SPECT images acquired after I-131 therapy. The influence of thyroid stimulating hormone (TSH) stimulation method on the kinetics was also evaluated.

Methods

A total of 57 patients who received I-131 therapy (2.96–7.4 GBq) were retrospectively included. TSH stimulation was achieved by recombinant human thyrotropin (rhTSH) or by thyroid hormone withdrawal (THW). Each patient received three sequential WBSs on days 1, 2, and 4 (or 5) after I-131 administration. All lesions were classified either as thyroid remnant (ThyR) or as metastatic lymph nodes (mLN) after considering the SPECT/CT images acquired during the last WBS. The lesion-based retention rate and absorbed dose of ThyR and mLN were calculated using a commercial dosimetric toolkit combined with the OLINDA software.

Results

The retention rate and the effective half-time of mLN were lower than that of ThyR (p < 0.001, p = 0.003). In addition, the retention rate and the effective half-time of ThyR in the rhTSH group were higher than those in the THW group (p < 0.001, p < 0.001). The differences in the retention rate and the effective half-time of mLN were not statistically significant between the THW group and rhTSH group (p = 0.549, p = 0.571).

Conclusions

Radioiodine therapy using rhTSH delivered an at least similar radiation dose to target lesions compared to using THW in thyroid remnants and metastatic lymph nodes.
Literature
1.
Hong CM, Lee WK, Jeong SY, Lee SW, Ahn BC, Lee J. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. Nucl Med Commun. 2014;35(11):1119–26.CrossRefPubMed
2.
Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37(4):821–8.CrossRefPubMed
3.
Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648–54.PubMed
4.
Ahn BC. Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer. Biomed Res Int. 2016;2016:1680464.PubMedPubMedCentral
5.
Oh JR, Ahn BC, Jeong SY, Lee SW, Lee J. Radioiodine scan index: a simplified, quantitative treatment response parameter for metastatic thyroid carcinoma. Nucl Med Mol Imaging. 2015;49(3):174–81.CrossRefPubMedPubMedCentral
6.
Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 2007;3(3):260–9.CrossRefPubMed
7.
Taieb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2010;95(7):3283–90.CrossRefPubMed
8.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023–7.PubMed
9.
Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics. 2000;20(2):533–46 (quiz 1–2).CrossRefPubMed
10.
Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43(4):313–23.PubMed
11.
American Thyroid Association Guidelines Taskforce on Thyroid Nodules, Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRef
12.
Hung BT, Huang SH, Huang YE, Wang PW. Appropriate time for post-therapeutic I-131 whole body scan. Clin Nucl Med. 2009;34(6):339–42.CrossRefPubMed
13.
Salvatori M, Perotti G, Villani MF, Mazza R, Maussier ML, Indovina L, et al. Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging. Nucl Med Commun. 2013;34(9):900–8.PubMed
14.
Rosario PW, Salles DS, Purisch S. Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. Arq Bras Endocrinol Metab. 2009;53(6):767–70.CrossRef
15.
Freudenberg LS, Fromke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes. 2010;118(7):393–9.CrossRefPubMed
16.
Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30(10):1371–7.CrossRefPubMed
17.
Potzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf). 2006;65(4):519–23.CrossRef
18.
Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43(11):1482–8.PubMed
19.
Van Nostrand D, Khorjekar GR, O’Neil J, Moreau S, Atkins FB, Kharazi P, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med. 2012;53(3):359–62.CrossRefPubMed
20.
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91(3):926–32.CrossRefPubMed
21.
Grimes J, Celler A, Shcherbinin S, Piwowarska-Bilska H, Birkenfeld B. The accuracy and reproducibility of SPECT target volumes and activities estimated using an iterative adaptive thresholding technique. Nucl Med Commun. 2012;33(12):1254–66.CrossRefPubMed
22.
Jentzen W, Moldovan AS, Ruhlmann M, Gorges R, Bockisch A, Rosenbaum-Krumme S. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Nuklearmedizin. 2015;54(3):137–43.CrossRefPubMed
23.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.CrossRefPubMed
24.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
Metadata
Title
I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal
Authors
Chae Moon Hong
Choon-Young Kim
Seung Hyun Son
Ji-hoon Jung
Chang-Hee Lee
Ju Hye Jeong
Shin Young Jeong
Sang-Woo Lee
Jaetae Lee
Byeong-Cheol Ahn
Publication date
01-10-2017
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 8/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-017-1188-x

Other articles of this Issue 8/2017

Annals of Nuclear Medicine 8/2017 Go to the issue

Original Article

Comparison of CTAC and prone imaging for the detection of coronary artery disease using CZT SPECT

Original Article

Comparison of Bayesian penalized likelihood reconstruction versus OS-EM for characterization of small pulmonary nodules in oncologic PET/CT

Original Article

High FDG uptake on PET is associated with negative cell-to-cell adhesion molecule E-cadherin expression in lung adenocarcinoma

Original Article

Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma

Original Article

Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy

Original Article

FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state